作者：宗石 来源：原创 发布日期：08-24
一 | CVS Health is planning to remove one type of a common decongestant from shelves after an advisory committee to the U.S. Food and Drug Administration said it was ineffective earlier this year.The products contain the oral formulation of phenylephrine (PE), which is found in several over-the-counter (OTC) medications.Although PE has been used as a decongestant for nearly a century, experts have been questioning its efficacy for years.The FDA Nonprescription Drugs Advisory Committee unanimously voted in September that PE did not improve nasal congestion any more than a placebo at the dosage given for OTC use.In response, CVS said it is removing products, in which PE is the only active ingredient from store shelves. This means products like Dayquil, which used a combination of active ingredients, will remain available for purchase."We are aware of the FDA Advisory Committee's position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations," CVS Health said in a statement. "We are removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores. Other oral cough and cold products will continue to be offered to meet consumer needs."CVS did not give specifies on brands that will be removed.The FDA told ABC News it has not yet determined whether it no longer considers PE to be a safe and effective medication and has not ordered the product to be removed from shelves. CVS's move is voluntary."The FDA has no further information to provide at this time regarding the timing of any decision the agency may make following the advisory committee meeting," the federal health agency said.The Consumer Healthcare Products Association told ABC News that the advisory committee's recommendation is a non-binding decision and not a change in regulation."FDA is currently in the process of reviewing the regulatory status of oral phenylephrine (PE) following September's advisory committee meeting," CHPA said in a statement. "Until FDA makes a determination on the committee's recommendation, oral PE remains a Category 1 OTC ingredient, which is generally recognized as safe and effective."Concerns were first raised about PE in 2007. Since then, evidence has accumulated showing that the drug offers little to no relief for nasal congestion.Experts believe this is because the body processes the drug before it reaches the nasal passages where it needs to work.It's unclear if other major retail pharmacy chains will follow in CVS's footsteps.Walgreens Boots Alliance would not disclose whether it was planning to remove products with PE from store shelves and said it would defer to the FDA."Walgreens follows FDA regulations. We are closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps," a Walgreens spokesperson told ABC News.Other major pharmacy chains including Albertsons, Costco and Kroger did immediately reply to ABC News' request for comment. Walmart did not have an answer immediately available.ABC News' Sasha Pezenik and Sony Salzman contributed to this report.。
二 | 央视网消息(新闻联播)：近日，中国工商银行、中国农业银行等多家商业银行发布公告，从8月1日起，每名借款人在同一家银行可享受的个人消费贷款和信用卡分期业务累计贴息上限由每年3000元提高到每年5000元。 信用卡消费贴息范围由信用卡账单分期扩展到汽车分期、装修分期等专项分期，以及消费分期、预借现金分期等各类分期产品。信用卡分期贴息的比例为年化1个百分点，且最高不超过办理相应信用卡分期业务时约定的折算年化利率的50%。 多家银行还明确，无论是个人消费贷款还是信用卡分期贴息，都不需要单独申请，银行识别是真实、合规的消费后，就能直接享受贴息。银行办理贴息服务不收取服务费。此外，8月1日到政策发布日之间已经办理的信用卡分期业务，可以联系银行申请补贴息。 提高个人消费贷款财政贴息额度上限、拓宽贴息范围，可降低居民消费信贷成本，与以旧换新等促消费政策叠加共振，进一步支持广大居民消费。 来源：央视网。
Current article:http://f10a.diaoengngtengdiachanpiezao.sbs/list_hvggc0/slz.html
Published on:10:24:47